MC0704 is a STAT3 Inhibitor for Triple-negative Breast Cancer Research
4.8 (227) · $ 8.99 · In stock
MC0704 is a STAT3 inhibitor (IC50=2.13 μM), which can be used for the research of metastatic triple-negative breast cancer (mTNBC).
RETRACTED ARTICLE: A new synthetic derivative of cryptotanshinone
PHT-7.3 is a Selective Inhibitor of Connector Enhancer of Kinase Suppressor of Ras 1 (Cnk1)
Brusatol (NSC 172924) is a Nrf2 Inhibitor
A combination of novel NSC small molecule inhibitor along with
Small molecule agents for triple negative breast cancer: Current
BCI-215 is a Tumor Cell-Selective DUSP-MKP Inhibitor
Zotatifin is a Selective and Well-Tolerated eIF4A (Protein Biogenesis) Inhibitor
NU6102 is a Potent CDK1 and CDK2 Inhibitor
BMS-P5 is an Orally Active PAD4 Inhibitor
MC0704, STAT3 Inhibitor
Selective inhibitory activity of 9l towards H3K79 methylation in
COTI-2 is an Orally Available Mutant p53 Activator
